EGFR+ Lung Cancer
Latest News
Latest Videos
CME Content
More News
Christina S. Baik, MD, MPH, discusses several existing and emerging treatment options for <em>ROS1</em>, <em>BRAF</em>, and <em>NTRK </em>genetic aberrations.
During a presentation at the 16th Annual Winter Lung Conference, Gregory J. Riely, MD, PhD, discusses how oncologists can differentiate between the many EGFR TKIs available for patients with <em>EGFR</em>-mutant non–small cell lung cancer.
General Cancer
Bristol-Myers Squibb has announced its decision to withdraw a supplemental biologics license application currently with the FDA seeking frontline approval for the combination of nivolumab and ipilimumab for patients with advanced non–small cell lung cancer with tumor mutational burden ≥10 mutations per megabase.
Heather A. Wakelee, MD, discusses the use of osimertinib as a frontline treatment option for patients with <em>EGFR</em>-positive lung cancer.
Both overall survival and progression-free survival were improved in patients with <em>EGFR</em>-mutant nonsquamous cell lung cancer who were treated with the combination of atezolizumab, bevacizumab, and chemotherapy compared with bevacizumab plus chemotherapy, according to an exploratory analysis of the IMpower150 study.
Patients who continued receiving osimertinib after their non–small cell lung cancer had progressed demonstrated a prolonged benefit beyond the initial progression event, according to a retrospective analysis of 118 patients from The University of Texas MD Anderson Cancer Center and the Moffitt Cancer Center and Research Institute.
Michael Gieske, MD, discusses how his community center was able to implement a lung cancer screening program.
A retrospective analysis of survival data from patients with metastatic non–small cell lung cancer showed that patients who received treatment at academic centers had better survival rates than those treated at community-based centers, and this disparity was more pronounced when patients were stratified by histology.
A supplemental biologics license application submitted to the FDA for atezolizumab, carboplatin, and nab-paclitaxel has been accepted. The application, based on findings from the phase III IMpower130 trial, is seeking the agent's approval for patients with metastatic nonsquamous non–small cell lung cancer.
D. Ross Camidge, MD, PhD, discusses the crowded landscape of oncogene-driven non–small cell lung cancer.
Increasing clinical relevance of less common gene signatures and alterations is leading to a benefit from broad-panel next-generation sequencing testing for patients with metastatic non–small cell lung cancer, according to an expert at Memorial Sloan Kettering Cancer Center.